



# Hollings Cancer Center

---

*Affiliate Program Offerings*



CONTENTS

About MUSC .....2

MUSC’s Affiliations Program .....3

    Key Tenets .....3

    Benefits of Partnering with MUSC .....3

    Affiliate Partner Model ..... 4

    MUSC Health Affiliate Program Offerings..... 4

MUSC’s Cancer Program .....5

    Overview.....5

    Leadership .....5

    Cancer Types ..... 6

    Treatment Programs..... 6

    Research & Shared Resources .....7

    Clinical Trials .....7

Service Offerings..... 8

Consultative Services .....9

    Branding Opportunities .....9

    Quality Oversight.....9

    Clinical Access .....10

    Consultative Offerings.....10

Comprehensive Services Model .....11

    Branding Opportunities .....11

    Staffing.....11

Faculty..... 12

Leadership and Faculty Bios..... 13

## ABOUT MUSC

The Medical University of South Carolina (MUSC) is dedicated to the pursuit of changing what's possible in health care. Nationally recognized for its innovation, patient- and family-centered care, and quality outcomes, this integrated health care system is accessible through a robust health system network, clinical affiliations and a nationally recognized telehealth network. MUSC experiences more than one million patient encounters annually, and its specialized care teams consistently rank among the best in the country. MUSC delivers transformational care shaped by world-class clinicians, health scientists, and educators who provide leading-edge care while developing the next generation of innovative health care leaders.

### MUSC AT A GLANCE

- South Carolina's only comprehensive academic medical center
  - › Over 16,000 team members
  - › \$2.6 billion annual operating budget
- Oldest medical school in the South; founded in 1824
  - › Six colleges with 3,000 students in all areas of health professions. Colleges include Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing, and Pharmacy
- Member of the prestigious National Institutes of Health (NIH) Consortium, which includes only the 60 best biomedical research institutions in the U.S.
- South Carolina's most comprehensive clinical enterprise offerings:
  - › 1,428-bed health system and 100 outreach locations
  - › 1+ million patient encounters per year
  - › One of only two National Centers for Excellence in Telehealth in the United States
  - › Hollings Cancer Center, one of only 70-National Cancer Institute NCI-Designated Cancer Centers in the U.S.

- › South Carolina's only solid organ transplant program (kidney, liver, heart)
- › Extracorporeal Life Support Center
- › SC's only nationally ranked children's hospital; that will open two new facilities in 2019
- › MUSC surgeons perform nearly 10,000 pediatric surgeries annually
- › Only pediatric Level 1 trauma center in the state; 25,000 visits annually to the emergency room
- › South Carolina's only Pediatric Burn Center
- › Advanced pediatric heart center with a 99% survival rate for complex surgeries

### MUSC HEALTH BY THE NUMBERS

**50,745**

Annual Surgical Cases

**1,428**

Combined number  
of patient beds

**58,028**

Annual Patient Admissions

Average  
Daily Census

**209,085**

Annual Emergency Room Visits

**926**

inpatients/day

**1.6 Million**

Annual Outpatient Visits

**1,500+**

Total Medical Staff

**675+**

Total Physicians  
in Training



## MUSC'S AFFILIATIONS PROGRAM

To honor MUSC Health's mission of preserving and optimizing human life in South Carolina and beyond through education, research and patient care, the vision for the MUSC Affiliations Program states:

---

**We extend MUSC Health's mission through the establishment of meaningful relationships locally, regionally and globally.**

---

### KEY TENETS

At MUSC, we believe that the following tenets drive a successful affiliation:

- **Health care is best provided locally.** To ensure this is possible, we will work with Affiliates to capitalize on their strengths and grow their clinical capabilities.
- For care that cannot be provided locally, we commit to timely patient access **and** timely, personal communication with referring physicians, supported by technology where appropriate.
- Physician-to-physician relationships are essential to any affiliate relationship. They will be prioritized through regular communication and collaboration.
- Affiliate relationships will be coordinated by a dedicated relationship manager. Integrated Centers of Clinical Excellence (ICCE) Chiefs (MUSC's physician service line leaders) will be accountable for the delivery of all clinical services.
- Affiliation agreements will contain clearly defined benefits and requirements to ensure that alignment and accountability are equally owned by both parties.


### BENEFITS OF PARTNERING WITH MUSC

MUSC provides health care organizations with opportunities to better serve their local communities and keep care in South Carolina, including:

- Support in the continual enhancement of clinical care and supplemental services for the community
- Assurance of continuity of care for patients that require tertiary or quaternary services
- VIP expedited access to hospitals, clinics, and health care providers throughout MUSC Health
- Greater leverage for contract negotiations and purchasing agreements (participation in a GPO)
- Guidance to enhance programmatic growth and operations
- Utilization of cobranding to leverage the recognition and reputation of MUSC within your community
- Access to educational and GME opportunities
- Support with physician and provider recruitment
- Support for population health initiatives including clinically integrated networks (CIN), ACOs, etc.
- Physician-to-physician relationships
- Access to electronic health record resources, including MUSC's Epic CareLink platform

## MUSC HEALTH AFFILIATE PROGRAM OFFERINGS


Based upon extensive market research and years of conversations with current and prospective affiliate partners, we have refined and tailored specific program offerings. These clinical offerings include:



Cancer



Heart &  
Vascular



Pediatrics



Neurosciences



Hospital based



Telehealth



GME

## AFFILIATE PARTNER MODEL

Affiliate partners invariably have unique combinations of strengths, capabilities and resources. Our goal is to design a program with our partners that capitalizes on strengths and utilizes resources in the community to deliver the highest value in a community cancer program. To this end, MUSC has developed two different partnership models to support the various needs of our affiliates:

- Consultative Services
- Comprehensive Services

Irrespective of the package chosen, every Affiliate organization will have a dedicated team focused on supporting the Affiliate's unique needs.

Each dedicated team will consist of:

- Relationship Manager: serves as the day-to-day MUSC Affiliations Contact, often coming onsite to meet with key stakeholders at the Affiliate organization and helping coordinate and communicate between the two entities
- ICCE Chief: works closely with the Affiliate organization's Chief Physician/Chair of Department (or equivalent roles) on clinical delivery components (staffing, tumor boards, chart rounds, clinical trials, etc.)
- Chief Medical Officer of Affiliate Network: partners with the Affiliate organization's Chief Medical Officer/Chief Quality Officer (or equivalent role) on all quality-related services
- Telehealth Liaison: works with the Affiliate organization to identify telehealth opportunities and implement MUSC telehealth programs at the Affiliate organization; acts as the day-to-day contact for all telehealth services and coordinates between the Affiliate organization and MUSC Health's Center for Telehealth

## MUSC HOLLINGS CANCER CENTER AFFILIATE PROGRAM OFFERINGS

### OVERVIEW


MUSC's Cancer Program combines two distinct components: MUSC Health's Oncology ICCE (Integrated Center of Clinical Excellence) and the MUSC Hollings Cancer Center (HCC), a National Cancer Institute-designated cancer center. Together, we strive to enhance the quality and breadth of clinical services, research, teaching, and other specialty services to communities across South Carolina.

### LEADERSHIP

MUSC's Cancer Program is led by a team of renowned physicians, researchers and administrators who have trained and served in prominent positions at some of the country's top cancer centers and academic medical institutions. Listed below are the clinical and administrative leaders that support the program.



**Gustavo W. Leone, Ph.D.**  
Director, Hollings Cancer Center



**David M. Mahvi, M.D.**  
Chief, Oncology Integrated Center of Clinical Excellence



**Carolyn Britten, M.D.**  
Chief of the Hematology/Oncology Division, Department of Medicine; Associate Director of Clinical Science, Hollings Cancer Center



**Joseph M. Jenrette, M.D.**  
Chair, Department of Radiation Oncology



**Tara Lock**  
Administrator, Oncology Integrated Center of Clinical Excellence, Hollings Cancer Center

### CANCER PROGRAM BY THE NUMBERS

**1,266**

Patients Enrolled  
in all Clinical Trials

**500**

Number of New Patient  
Referrals Per Month

**16**

Number of  
care sites

**236**

Patients to treatment  
trials in 2018

**82**

Physicians in  
Oncology ICCE

### QUALITY AND AWARDS



## CANCER TYPES

As a nationally recognized cancer center and the leading cancer program in South Carolina, MUSC Hollings Cancer Center combines the full range of cancer specialties to deliver a higher level of care to the patients we serve. We treat all cancer types and have created the following multidisciplinary cancer programs to provide comprehensive and coordinated patient care.

## TREATMENT PROGRAMS

As the state's only NCI-Designated Cancer Center, MUSC offers innovative and best-practice treatment options for patients through the following programs:

### Medical Oncology

Chemotherapy at MUSC Hollings Cancer Center is administered by our team of Fellowship-trained Medical Oncologists, each specializing in different cancer types. Patients are seen at MUSC Hollings Cancer Center and MUSC Health East Cooper Medical Pavilion.

### Radiation Oncology

MUSC Health Radiation Oncology has a wide variety of modern technology enabling us to treat our patients with leading-edge techniques, advanced clinical protocols and the latest in innovative research and clinical trials, such as: TrueBeam STx, Gamma Knife, Brachytherapy, and Tomotherapy.

MUSC offers Radiation Oncology treatments at four different facilities: MUSC Hollings Cancer Center in downtown Charleston, MUSC Health East Cooper Medical Pavilion in Mt. Pleasant, MUSC Health Tideland Health in Murrells Inlet, and MUSC Health at Beaufort Memorial Hospital in Beaufort.

### Surgery

MUSC Hollings Cancer Center offers a team of surgeons who specialize in treating cancer patients, including fellowship-trained surgical oncologists. We are at the forefront of laparoscopic and endoscopic techniques for cancer surgeries. These minimally invasive techniques improve precision and reduce the surgical impact on patients, including the reduction of tissue damage and post-surgical pain while promoting a faster recovery.

A team of surgical oncologists are specially trained in the use of the da Vinci® Surgical System, a robot that helps to increase surgical precision and shorten recovery time. This device is being used to treat head and neck, prostate, thoracic, and gynecologic cancers.

### Blood & Marrow Transplant

In 2018, South Carolina's leader in bone marrow and stem cell transplantation, MUSC Bone Marrow Transplant, was nationally recognized by Press Ganey as the Team of the Year. We are the only combined adult and pediatric FACT (Foundation for Accreditation of Cellular Therapy) Accredited and NCI-Designated Cancer Center in the state.

MUSC's experience and innovation with adult and pediatric blood and marrow transplantation have resulted in outcomes that are among the best in the country. Our internationally recognized team of specialists and researchers have reduced associated complications, making transplantation possible for people not previously eligible. As a pioneer in blood and marrow transplant research, MUSC is the definitive source offering hope for adult and pediatric patients battling Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, multiple myeloma and other diseases. We are one of only a few U.S. programs to have used bone marrow to treat autoimmune diseases, sickle cell disease and other red blood cell-related diseases.



## Hollings Cancer Center

An NCI-Designated Cancer Center

### RESEARCH PROGRAMS

- Cancer Biology
- Cancer Immunology
- Developmental Cancer Therapeutics
- Cancer Control

### SHARED RESOURCES

- Lipodomics
- Cell Evaluation & Therapy
- Cell & Molecular Imaging
- Biorepository & Tissue Analysis
- shRNA
- Genomics
- Biostatistics

### RESEARCH & SHARED RESOURCES

MUSC Hollings Cancer Center (HCC) is home to more than 120 scientists conducting research and collaborating on better ways to prevent, detect, diagnose and treat these complex diseases. As one of 70 National Cancer Institute-Designated Cancer Centers, HCC continues to attract top cancer researchers from leading institutions across the country who are conducting research in the community, laboratory and clinic.

### CLINICAL TRIALS

Clinical trials are the foundation for advancement in cancer treatments. The MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. With our ability to offer clinical trials and therapies not available elsewhere in South Carolina, including phase I trials, patients receive access to the most appropriate, up-to-date treatments, giving them the best chance of long-term survival.



## SERVICE OFFERINGS

High-level details of each partnership model are included in the matrix below. More detailed descriptions around the specific service offerings included can be found in the subsequent pages.

Cancer Service Offerings	Cancer Service Line Affiliations Partnership Models	
	Consultative Services Model	Comprehensive Services Model
Price	\$60,000 per quarter*	\$60,000 per quarter*
Branding	<div>Cancer Brand</div> <div>MUSC Health Affiliate</div>	<div>System Brand</div> <div>  <b>MUSC Health</b>            Medical University of South Carolina         </div>
Quality Oversight	✓	✓
Tumor Boards	✓	✓
Radiotherapy Chart Rounds	✓	✓
Clinical Access	✓	✓
Clinical Program Review	✓	✓
Optional Service Offerings – at Additional Cost		
Consultative – Departmental Support Services	✓	✓
Clinical Staffing Options		
Radiation Oncology	N/A	✓
Medical Oncology	N/A	✓
Infusion	N/A	✓
Potential Joint Venture	N/A	✓

\*This price represents the base Affiliation quarterly fees. Any additional fees and expenses related to optional service elements are excluded. The final fee structure will be dependent upon the services selected and will be delineated as a component of the Affiliation agreement.

## CONSULTATIVE SERVICES MODEL

MUSC created this model to serve the needs of Affiliate organizations who have their own programs and clinical staff, but, wish to have MUSC help provide quality oversight and programmatic support.

### BRANDING OPPORTUNITIES

MUSC Health is excited to share our brand with those who broaden our commitment to high-quality, patient-centered care. The extent of the opportunity within this model is limited and is pursuant upon MUSC oversight and management of a comprehensive quality program. MUSC Health will work with affiliate organizations to understand branding requests and assist with determining the most appropriate usage.

### QUALITY OVERSIGHT

In today's health care environment, a robust quality program is essential for health care delivery systems to ensure the system is delivering the very best care to their patients; care which is safe, timely, efficient, effective, equitable, and patient centered. In addition, health care payment models are moving rapidly from fee-for-service to value-based payments, making high quality care a prerequisite to financial performance. To this end, MUSC will work collaboratively with the Affiliate organization to develop a comprehensive quality program and if appropriate, implement a full-scale Quality Assurance and Performance Improvement (QAPI) program — a systematic, comprehensive, and data-driven approach to improving safety and quality in a health care system.

For our Cancer Affiliates, MUSC will provide the following Oncology-specific quality offerings:

#### Tumor Board

All new cancer cases seen by MUSC Affiliate providers must be presented at a MUSC tumor board. Tumor board ensures that all new medical and surgical oncology cancer patients are reviewed by a multidisciplinary team and that all treatment options are considered, therefore ensuring that the patient is placed in the correct treatment protocol and given the greatest likelihood of successful treatment. MUSC will work closely with the Affiliate organization to establish tumor board participation. Options include MUSC participation at a local site, consulting with the Affiliate tumor board or case submission for review by MUSC tumor boards. Possibilities will include a community oncology board comprised of all of MUSC's affiliate sites with a focus on medical oncology, and subspecialty tumor boards at MUSC focused more broadly on comprehensive care of more rare cancers.

#### Radiotherapy Chart Rounds

All new radiation oncology patients will be presented at MUSC radiotherapy chart rounds. Chart rounds ensure that patients are continuing on the correct treatment protocol, and that all treatment-related side effects are adequately managed. MUSC will work closely with the Affiliate organization to establish a system for submitting and reviewing cases.

#### Evidence-Based Pathways & Protocols

Given that all new cancer cases seen by Affiliate providers will be presented to MUSC tumor board and chart rounds, MUSC will leverage evidence-based pathways and protocols when making recommendations for care plans.

## CLINICAL ACCESS

Providing timely clinical access is paramount in ensuring the highest level of patient care. To ensure that our Affiliates have access to the care they need, MUSC is prepared to offer the following services.

### Expedited Admission and Scheduling

MUSC believes that the best care is provided locally. However, when an Affiliate provider wishes to have one of their patients seen by an MUSC specialist in Charleston, or desires to have a quick consult with an Oncologist sub-specialist, MUSC wants the process to be easy to navigate and efficient. To this end, MUSC has established a specialized team that will take calls and help expedite the request.

### Clinical Trials

Clinical trials are the foundation for advancement in cancer treatments. As an NCI-Designated Cancer Center, Hollings Cancer Center is part of a national network of clinical trials, with access to hundreds of trials across the United States. Through our process of tumor board presentations and chart reviews, every patient with a new cancer diagnosis will be considered for applicable clinical trials and offered participation. This opens access to treatment options that are not available anywhere else in the state and assures patients that they are getting the most up-to-date, appropriate treatments, ensuring the best chance of long-term survival.

### Palliative Care

Cancer and its treatment often cause serious side effects. MUSC's Palliative Care Program offers the complete range of treatments to improve quality of life for adults and children living with serious illnesses. All appropriate patients seen by Affiliate providers can be referred to MUSC's Palliative Care Program and receive care through Tele-Palliative services.

Additionally, MUSC will provide the guidance and support to help the Affiliate organization develop their own Palliative Care Program locally.

### Advanced Testing

MUSC Health offers an extensive laboratory test menu to support the diagnostic needs of Affiliate partners. MUSC has testing and clinician expertise in a variety of specialties, including but not limited to:

- clinical chemistry
- cytogenetics
- flow cytometry
- genomics
- hematology
- HLA
- immunology
- microbiology
- molecular genetics
- molecular pathology
- toxicology
- transfusion medicine

### Advanced Imaging

MUSC Radiologists are involved in every step of cancer care, from cancer screening and diagnosis to treatment and follow-up. Beyond PET/CT diagnostics and scans, MUSC's Interventional Radiologists combine competence in imaging, image-guided minimally invasive procedures, and periprocedural patient care to diagnose and treat benign and malignant conditions of the thorax, abdomen, pelvis, and extremities. Therapies include embolization, angioplasty, stent placement, thrombus management, drainage, and ablation, among others.

## CONSULTATIVE OFFERINGS

Building a strong community cancer program can be challenging. To help our Affiliates develop and grow successfully, MUSC is offering a full suite of hands-on consultative services:

### Clinical Program Review

As a component of the relationship, MUSC will partner with the Affiliate to conduct a thorough programmatic review of oncology-specific clinical and operational

workflows and processes, staffing models, support service capabilities, and quality outcomes for the radiation oncology and medical oncology programs and, if appropriate, the infusion center. The work will commence early in the relationship and will likely take place as a multi-day, on-site visit. The on-site review will be followed up with a detailed report outlining opportunities for optimization and MUSC best-practice recommendations. We will then establish goals to optimize improvements and offer quarterly check-ins to help drive progress and instill accountability.

### Departmental Support Services

MUSC wishes its Affiliates to be as successful as possible and is pleased to offer additional departmental consulting services upon request. These could include, but are not limited to, projects related to service line development, CON support, and the revenue cycle. Similar to the Clinical Program Review, these assessments will result in a detailed report with identified opportunities for optimization and MUSC best-practice recommendations.

## COMPREHENSIVE SERVICES MODEL

MUSC created this model to serve the needs of Affiliate organizations who wish MUSC to staff and operate their cancer program. Think of this offering as ‘MUSC On-site’ in your local community. To accomplish this, MUSC will offer all the services of the Consultative Services Model as well as provide the staff, equipment and processes to manage and operationalize your community cancer program.

### BRANDING OPPORTUNITIES

At MUSC Health, we have invested in building South Carolina’s most nationally recognized health system brand. We believe that even greater brand value can be achieved by working collaboratively with the best strategic partners to improve safety scores, quality ratings, patient perception and awareness. Leveraging strong brand names through cobranding brings greater value to both parties.

### STAFFING

Finding highly trained oncology staff is challenging — even more so if the community is small or the Affiliate

organization is still nascent in its oncology program development. MUSC is prepared to handle all the direct recruiting, staffing and credentialing for our Affiliate’s programmatic needs:

#### Provider Staffing

Regardless of whether the Affiliate needs to have one additional oncologist to help with demand and balance the call rotation or needs to secure a complete oncology provider team, MUSC stands ready to meet the needs for each program (Radiation Oncology, Medical Oncology, and Infusion).

#### Programmatic Staffing & Recruiting

MUSC appreciates the importance of staff recruitment and retention and has established a designated team within our Oncology ICCE who will partner with Affiliates to understand job requirements, staffing counts, necessary credentials, etc., and will create a plan to fill the gap — be it deploying MUSC resources as interim staff, placing MUSC staff on-site as employees, or partnering to create a dynamic recruiting and onboarding program.

## FACULTY

Each cancer specialty and treatment program are led by a Division Director, listed below:



**Andrea Abbott, M.D.**  
Division Director of  
Melanoma & Skin Cancers



**Ramsay Camp, M.D.**  
Division Director of  
Gastrointestinal Cancers



**Nancy DeMore, M.D.**  
Division Director of Breast  
Cancer



**Evan Graboyes, M.D.**  
Division Director of Head  
& Neck Cancers




**Robert Grubb, M.D.**  
Division Director of  
Genitourinary Cancers



**Michelle Hudspeth, M.D.**  
Division Director of Pediatric  
Hematology/Oncology



**Lee Leddy, M.D.**  
Division Director of  
Sarcoma



**Young Lee, M.D.**  
Division Director of  
Medical Oncology



**Scott Lindhorst, M.D.**  
Division Director of Brain &  
Spine Cancers



**David Marshall, M.D.**  
Division Director of  
Radiation Oncology



**Gerard Silvestri, M.D.**  
Division Director of Lung &  
Thoracic Cancers



**Robert K. Stuart, M.D.**  
Division Director of  
Hematology



## LEADERSHIP BIOS

### **Carolyn Britten, M.D.**

Chief, Hematology/Oncology Division, Department of Medicine

Dr. Britten is Chief of the Division of Hematology/Oncology in the Department of Medicine at MUSC and holds the Charles Westfield Coker Distinguished Endowed Chair, supported by the South Carolina SmartState® Center of Excellence in Gastrointestinal Malignancies. As Associate Director, she oversees the entire clinical research enterprise at Hollings. As a nationally recognized phase I clinical trials expert, she is charged with facilitating the efforts to bring scientific discoveries from Hollings scientific laboratories to clinical applications through clinical trials.

### **Joseph M. Jenrette, M.D.**

Chair, Department of Radiation Oncology

Dr. Jenrette has been involved in cancer — care at MUSC for over 30 years. His primary interests in cancer have been cancers of women — including breast and gynecological cancers of children — as well as all types of solid cancers and brain tumors. Most of his efforts at this time, however, concern treating patients with Gamma Knife technology. The MUSC Gamma Knife team consists of a neurosurgeon, a radiation physicist and Dr. Jenrette — a radiation oncologist. The team treats a large variety of diseases, including malignant brain tumors as well as non malignant brain tumors. Additionally, we treat a number of vascular tumors in the brain.

### **Gustavo W. Leone, Ph.D.**

Director, Hollings Cancer Center

Dr. Leone joined MUSC in 2017 as the Hollings Cancer Center Director, after relocating from the Ohio State University Comprehensive Cancer Center. He is a professor of biochemistry and molecular biology, holds the Grace E. DeWolff Endowed Chair in Medical Oncology, and serves as the Senior Associate Dean for Oncology in the College of Medicine. As Director, Dr. Leone oversees the patient care arm of the Hollings Cancer Center and leads cancer-related research efforts in order to achieve and promote transdisciplinary and translational collaborative research. Dr. Leone's research focuses on identifying how disruption of critical cell cycle regulatory pathways contributes to uncontrolled cell growth, a hallmark of cancer. He has authored more than 120 peer-reviewed publications and has received numerous recognitions for his contributions to cancer research.

### **Tara Lock**

Administrator, Oncology Integrated Center of Clinical Excellence

Tara Lock is the Administrator of the Oncology ICCE at MUSC. She holds a bachelor's degree in business & philosophy from Eastern Washington University and a master's degree in hospital administration from Washington State University. She worked in imaging for several years, including work for the University of Washington Medical Center and the Virginia Mason Medical Center. She then served as the director of the Olympic Medical Cancer Center in Washington State, beginning in 2009. Tara next became Director of Operations for the Southcoast Health System, where she oversaw two cancer centers within a three-hospital system. She implemented the first financial counseling program within oncology and demonstrated the value of the position repeatedly, both inside and outside the Southcoast Health System. Tara chaired the finance committee of the Association of Community Cancer Centers and assisted them in developing tools that financial counselors across the country use today. She has been an invited speaker at numerous events across the country, where she has shared her knowledge and experience in the development of similar programs in other health care organizations.

### **David M. Mahvi, M.D.**

Chief, Oncology Integrated Center of Clinical Excellence

Dr. Mahvi serves as Chief of the Oncology Integrated Center of Clinical Excellence (ICCE) and Chief of Surgical Oncology. In his leadership role, Dr. Mahvi oversees the clinical activities and performance of the Hollings Cancer Center. In coordination with MUSC leadership, faculty, physicians and staff, Dr. Mahvi executes strategies for program development, growth and patient access as well as managing the financial efforts of clinical operations.

## FACULTY BIOS

### **Andrea Abbott, M.D.**

Division Director, Melanoma & Skin Cancers

Dr. Abbott is a board-certified surgical oncologist who specializes in the treatment of breast cancer, melanoma and nonmelanoma skin cancers, and soft tissue sarcoma. Dr. Abbott obtained her medical degree from the University of Missouri–Kansas City and completed her general surgery residency at the University of Minnesota. She also obtained a master's degree in clinical research from the University of Minnesota. She completed her surgical oncology fellowship at Moffitt Cancer Center in Tampa, Florida.

In addition to her surgical practice, Dr. Abbott is involved in clinical research and evaluating ways to improve information delivery to patients in order to enhance the patient-physician relationship and decision-making process. She is also working on ways to reduce opioid addiction after cancer surgery.

### **Ramsay Camp, M.D., FACS**

Division Director, Gastrointestinal Cancers

Dr. Camp is an associate professor of surgery in the Section of Surgical Oncology at the Medical University of South Carolina. He completed his undergraduate degree at Davidson College and his medical degree at the Medical University of South Carolina. He performed general surgery training at Shand's Hospital at the University of Florida and completed a surgical oncology fellowship at the University of Texas M.D. Anderson Cancer Center. Since becoming a faculty member in 2007, he has helped develop the melanoma and skin cancer program and currently serves as the program leader. Dr. Camp has an active research laboratory with a focus on mechanisms of chemotherapy and radiation resistance. He is a fellow of the American College of Surgeons and a member of various oncology societies, including the Society of Surgical Oncology, American Society of Clinical Oncology, American Association of Cancer Research, National Surgical Adjuvant Breast and Bowel Project (NSABP), Southwest Oncology Group (SWOG), and American College of Surgeons Oncology Group (ACOSOG).

### **Nancy DeMore, M.D.**

Division Director, Breast Cancer

Dr. DeMore is a board-certified breast surgical oncologist and is the BMW Endowed Chair in Cancer Research at MUSC Health. As a surgeon, Dr. DeMore has played an integral role in the evaluation of minimally invasive techniques that have changed the standard of care for patients who require sentinel lymph node biopsy. Furthermore, she has expanded the indications for breast conservation by advancing the use of neoadjuvant chemotherapy (cancer-killing drugs taken before primary therapy). As a physician-scientist, Dr. DeMore has been a coinvestigator on 11 active clinical trials and 24 completed clinical trials which have led to clinical advances in the care of breast cancer patients, in particular those with metastatic breast cancer. Dr. DeMore has been appointed to a six-year term on the NIH Oncology 2, Translational Clinical IRG, Cancer Immunopathology and Immunotherapy Study Section.

Dr. DeMore obtained her medical degree from Chicago Medical School. She completed her residency at Boston University Medical Center, a cancer research fellowship at Harvard Medical School, and fellowship training at Memorial Sloan Kettering Cancer Center. Dr. DeMore practiced as a professor of surgery at the University of North Carolina-Chapel Hill for 13 years.

### **Evan Graboyes, M.D.**

Division Director, Head & Neck Cancers

Dr. Graboyes is a head and neck oncologic surgeon. Dr. Graboyes graduated summa cum laude from Princeton University, with degrees in philosophy and public policy. He then completed his medical degree and residency at the Washington University School of Medicine. He completed his fellowship in head and neck oncologic and reconstructive surgery at MUSC.

Dr. Graboyes's specific areas of expertise include regional and microvascular free flap reconstruction for tumors of the oral cavity, pharynx, and larynx; advanced melanoma and nonmelanoma skin cancers; and lesions of the salivary glands.

Dr. Graboyes is a member of numerous national committees for the American Academy of Otolaryngology–Head and Neck Surgery as well as the American Head and Neck Society. He is board certified by the American Board of Otolaryngology.

**Robert Grubb, M.D.**

Division Director, Genitourinary Cancers

Dr. Grubb graduated from Davidson College and attended Emory University School of Medicine. He completed surgery and urology training at Barnes-Jewish Hospital/Washington University before pursuing fellowship training in urologic oncology at the National Cancer Institute. Dr. Grubb then returned to the Washington University School of Medicine as a member of the urology faculty. At Washington University, Dr. Grubb performed prostate cancer epidemiology research and contributed to the PLCO Cancer Screening Trial. Dr. Grubb has also studied imaging of genitourinary cancers. Clinically, in addition to managing patients with kidney, bladder, and prostate cancer, he is Chief of Urology at the St. Louis VA Medical Center.

**Michelle Hudspeth, M.D.**

Division Director, Pediatric Hematology/Oncology

Dr. Hudspeth is a graduate of the MUSC College of Medicine and completed her residency, chief residency and fellowship at the Johns Hopkins Hospital and the National Cancer Institute. She is the division chief for pediatric hematology/oncology, the director of the pediatric blood and marrow transplant program, and the quality director for the combined adult and pediatric blood and marrow transplant program. She is the institutional principal investigator for Pediatric Blood and Marrow Transplant Consortium trials and a member of the Pediatric Blood and Marrow Transplant Consortium GVHD committee and supportive care committee. She also serves on several working committees (GVHD, pediatric cancer, and immune deficiencies/inborn errors of metabolism) for the Center for International Blood and Marrow Transplant Research.

**Lee Leddy, M.D.**

Division Director, Sarcoma

Dr. Leddy received a bachelor's degree in biological science from Emory University while also lettering on the varsity basketball team. He then received a medical degree from the University of Florida College of Medicine. Dr. Leddy returned to Emory University to complete his internship and residency in the Department of Orthopaedic Surgery. He joined MUSC in 2009, after completing a fellowship in orthopaedic oncology at Emory University, where he helped establish the sarcoma program. He is currently the leader of the Sarcoma Disease Focus Team at Hollings Cancer Center and serves as the residency program director for the Department of Orthopaedics. He is actively involved in both clinical and basic science research and collaborates with members of the Sarcoma Immunotherapy Lab.

As a member of the MUSC Department of Orthopaedic Surgery, Dr. Leddy focuses on providing excellent care to patients with benign and malignant bone and soft tissue tumors and metastatic bone cancer, providing fracture care, and performing primary and revision hip and knee replacements.

**Young Lee, M.D.**

Division Director, Medical Oncology

Dr. Lee received her medical degree from the Federal University of Rio Grande do Sul Medical School, Brazil, and completed her internship and residency in internal medicine at Jackson Memorial Hospital, University of Miami. She also completed a fellowship in hematology and oncology at Jackson Memorial Hospital, University of Miami. She is board certified in hematology and oncology.

Dr. Lee has served as an assistant professor of medicine at the Sylvester Cancer Center, University of Miami, and as director of the Jackson Memorial Breast Health Center. She was an assistant professor of medicine at the Greenebaum Cancer Center, University of Maryland, and then became Chief of Oncology at Harbor Hospital. She also served as the medical director of the Breast and Cervical Cancer Program for Baltimore City.

Inspired by her father, she completed The Structural Acupuncture Course for Physicians at Harvard Medical School in 2012. She treats patients holistically and was a pioneer in the use of scalp-cooling caps for prevention of hair loss during chemotherapy.

Dr. Lee is a cofounder of capsoflove.org, a nonprofit organization that provides financial assistance to breast cancer patients who cannot afford the hair-saving technology. She is also a member of the American Society of Clinical Oncology.

## FACULTY BIOS — *continued*

### **Scott Lindhorst, M.D.**

Division Director, Brain & Spine Cancers

Dr. Lindhorst is a neuro-oncologist who joined MUSC in August 2013. His primary appointment is in the Department of Neurosurgery, and he holds a dual appointment as an assistant professor in the Department of Medicine, Division of Hematology/Medical Oncology.

Dr. Lindhorst received a bachelor's degree in microbiology from the University of Florida and a medical degree from the University of South Alabama College of Medicine. He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the University of Alabama Birmingham School of Medicine. He also completed a fellowship in neuro-oncology at Duke University Medical Center. Dr. Lindhorst received clinical trials training at Massachusetts General Hospital, focusing on patients with amyotrophic lateral sclerosis.

He is board certified in general internal medicine, hematology and medical oncology by the American Board of Internal Medicine. He is also board certified in neuro-oncology by the United Council for Neurologic Subspecialties. His practice focuses on patients with primary and metastatic malignancies of the central nervous system, and he also runs numerous clinical trials for these patients, aiding in the search for new cancer treatments.

### **David Marshall, M.D.**

Division Director, Radiation Oncology

Dr. Marshall is a board-certified radiation oncologist specializing in genitourinary (GU) and gastrointestinal (GI) cancers. He was recognized by Castle Connolly as a top doctor in radiation oncology in 2016 and 2017. Dr. Marshall has published widely on GI and GU cancers and has brought innovative treatment options to the people of South Carolina, including Y-90 microsphere therapy and radiosurgical treatment for liver cancers and the use of linked seeds for prostate brachytherapy.

Dr. Marshall is the director of the radiation oncology resident training program at MUSC. He also functions as the deputy associate director for clinical investigations at the Hollings Cancer Center. He is active in several national scientific and professional organizations, including the Association of Directors of Radiation Oncology Programs, the American Society for Radiation Oncology, the American Society for Clinical Oncology, the American Radium Society, the American Brachytherapy Society, the Southwestern Oncology Group, and NRG Oncology.

### **Gerard Silvestri, M.D.**

Division Director, Lung & Thoracic Cancers

Dr. Silvestri is a professor of medicine and a lung cancer pulmonologist at the Medical University of South Carolina. He completed his undergraduate education at Fairleigh Dickinson University, his medical degree at St. Georges University, a residency in internal medicine at the Hospital of St. Raphaels/Yale University School of Medicine, and fellowship training at Dartmouth. He also has an advanced degree in health services research from Dartmouth.

Dr. Silvestri began the first multidisciplinary lung cancer clinic in South Carolina and now evaluates five to seven new lung cancers per week. His clinical research is patient oriented and comprehensive, and he was part of the first group to publish the utility of endoscopic ultrasound with fine-needle aspiration of mediastinal lymph nodes to stage lung cancer patients.

Dr. Silvestri has been a section editor and author of the American College of Chest Physicians (ACCP) evidence-based guidelines on the diagnosis and management of lung cancer. He has also lectured as a master clinician in lung cancer for both the ACCP and the American Thoracic Society (ATS) and has served as chair of the Thoracic Oncology Network of the ACCP.

**Robert K. Stuart, M.D.**

Division Director, Hematology

Dr. Stuart graduated from the Johns Hopkins University School of Medicine and undertook internal medicine training at Johns Hopkins Hospital. He completed a medical oncology fellowship at the Johns Hopkins Oncology Center and a research fellowship in the laboratory of developmental hematopoiesis at the Memorial Sloan Kettering Cancer Center before being appointed assistant professor of oncology and medicine at Johns Hopkins and, later, associate professor of oncology and medicine at Johns Hopkins.

In 1985, Dr. Stuart was named professor of medicine and founding director of the Hematology/Oncology Division of MUSC, and he established an accredited hematology/oncology fellowship training program in 1986. He played a key role in the development of the Ernest F. Hollings Cancer Center, for which he served as the associate director for clinical trials. He also established a cancer clinical trials program, resulting in MUSC becoming an affiliate member of Cancer and Leukemia Group B (CALGB), a main member of CALGB, and then a main member of SWOG (formerly Southwest Oncology Group).

In 1997, Dr. Stuart was named chairman of the Department of Oncology at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia, where he directed over 70 physicians from 19 countries. Dr. Stuart returned to MUSC in 2001, as a professor of medicine in the Hematology/Oncology Division, where he is director of the clinical component of the Hollings Cancer Center's hematological malignancies program, director of the blood and marrow transplant (BMT) program, and medical director of the clinical trials office.

Dr. Stuart is certified in internal medicine, medical oncology and hematology by the American Board of Internal Medicine. He is a founding director of the Aplastic Anemia & MDS (Myelodysplastic Syndrome) International Foundation and has received the American Society of Hematology's Champions of Advocacy Award, the Leukemia & Lymphoma Society's Partners in Progress Award, and the MUSC Foundation's Outstanding Clinician Award and Distinguished Faculty Service Award. He has been elected by his peers for inclusion in Best Doctors in America since 1996.





For additional information please contact

**Matthew J. Severance, MBA, MHA, FACHE**

Chief of Affiliations and Network Development

[severance@musc.edu](mailto:severance@musc.edu) | Office 843-792-8877



Changing What's Possible